Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus

Serum Pentraxin-3 in Non-alcoholic Fatty Liver Disease With or Without Hepatitis C Virus: A Comparative Egyptian Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03276039

Enrollment

Registered

2017-09-08

Start date

2014-04-15

Completion date

2016-07-30

Last updated

2017-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Alcoholic Fatty Liver Disease

Brief summary

This study included 70 subjects divided into 3 groups. Group I included 25 patients with NAFLD. Group II included 25 patients with NAFLD and chronic HCV. Group III: included 20 controls. Abdominal ultrasound was done to patients and controls. Plasma pentraxin-3 (PTX3) was measured using ELISA. Comparison between three groups was done regarding plasma pentraxin-3. Higher levels of plasma PTX3 were detected in NAFLD patients irrespective of presence or absence of chronic HCV infection. Plasma PTX3 could be used as a non-invasive test for prediction of metabolic syndrome in the high-risk population with high sensitivity and moderate specificity.

Interventions

DIAGNOSTIC_TESTplasma pentraxin-3

Plasma pentraxin-3 was measured using ELISA

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Yes

Inclusion criteria

* Patients with NAFLD. * Patients with NAFLD and chronic hepatitis C viral infection.

Exclusion criteria

* Current or past consumption of significant amount of alcohol more than 21 drinks and 14 drinks per week for men and women respectively. * Patients receiving Drugs which cause fatty liver as amiodarone, diliazem, tamoxifen, steroids. * Patients who take statins as it has lowering effect on plasma PTX3. * Patients having any clinical evidence of hepatic decompensation, such as hepatic encephalopathy, ascites, variceal bleeding, elevated serum bilirubin level to more than two folds the upper limit of normal. * Patients with heart failure. * Patients with autoimmune rheumatic disease. * Patients with chronic kidney diseases. * Patients with sepsis.

Design outcomes

Primary

Measure	Time frame	Description
Plasma pentraxin-3 as a non invasive diagnostic marker in diagnosis of NAFLD in comparison to it's levels in patients with NAFLD and chronic hepatitis C viral infection	1 year	Measurement of plasma pentraxin-3 in patients with NAFLD in comparison to it's levels in patients with hepatic steatosis on top of HCV and normal controls

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026